دورية أكاديمية
cGAS-STING signalling in cancer: striking a balance with chromosomal instability.
| العنوان: | cGAS-STING signalling in cancer: striking a balance with chromosomal instability. |
|---|---|
| المؤلفون: | Beernaert B; Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K., Parkes EE; Department of Oncology, University of Oxford, Old Road Campus Research Building, Oxford OX3 7DQ, U.K. |
| المصدر: | Biochemical Society transactions [Biochem Soc Trans] 2023 Apr 26; Vol. 51 (2), pp. 539-555. |
| نوع المنشور: | Journal Article; Research Support, Non-U.S. Gov't; Review |
| اللغة: | English |
| بيانات الدورية: | Publisher: Portland Press On The Behalf Of The Biochemical Society Country of Publication: England NLM ID: 7506897 Publication Model: Print Cited Medium: Internet ISSN: 1470-8752 (Electronic) Linking ISSN: 03005127 NLM ISO Abbreviation: Biochem Soc Trans Subsets: MEDLINE |
| أسماء مطبوعة: | Original Publication: London : Portland Press On The Behalf Of The Biochemical Society |
| مواضيع طبية MeSH: | Chromosomal Instability* , Neoplasms*/genetics , Neoplasms*/metabolism, Humans ; Immunity, Innate/genetics ; Inflammation ; Nucleotidyltransferases ; Signal Transduction ; Tumor Microenvironment |
| مستخلص: | Chromosomal instability (CIN) is a hallmark of cancer that drives tumour evolution. It is now recognised that CIN in cancer leads to the constitutive production of misplaced DNA in the form of micronuclei and chromatin bridges. These structures are detected by the nucleic acid sensor cGAS, leading to the production of the second messenger 2'3'-cGAMP and activation of the critical hub of innate immune signalling STING. Activation of this immune pathway should instigate the influx and activation of immune cells, resulting in the eradication of cancer cells. That this does not universally occur in the context of CIN remains an unanswered paradox in cancer. Instead, CIN-high cancers are notably adept at immune evasion and are highly metastatic with typically poor outcomes. In this review, we discuss the diverse facets of the cGAS-STING signalling pathway, including emerging roles in homeostatic processes and their intersection with genome stability regulation, its role as a driver of chronic pro-tumour inflammation, and crosstalk with the tumour microenvironment, which may collectively underlie its apparent maintenance in cancers. A better understanding of the mechanisms whereby this immune surveillance pathway is commandeered by chromosomally unstable cancers is critical to the identification of new vulnerabilities for therapeutic exploitation. (© 2023 The Author(s).) |
| References: | Cell Rep. 2015 May 19;11(7):1018-30. (PMID: 25959818) Proc Natl Acad Sci U S A. 2021 Nov 23;118(47):. (PMID: 34799452) Mol Cancer Res. 2019 Apr;17(4):974-986. (PMID: 30587523) Proc Natl Acad Sci U S A. 2021 Apr 13;118(15):. (PMID: 33827917) Nat Commun. 2018 Jul 9;9(1):2658. (PMID: 29985392) Cell. 2011 Feb 18;144(4):499-512. (PMID: 21315436) Cancer Discov. 2021 May;11(5):1212-1227. (PMID: 33372007) Biomolecules. 2020 Nov 15;10(11):. (PMID: 33203188) Cell Death Discov. 2018 Feb 7;4:10. (PMID: 29531807) Int J Mol Sci. 2021 Nov 25;22(23):. (PMID: 34884568) Proc Natl Acad Sci U S A. 2017 Jun 6;114(23):E4612-E4620. (PMID: 28533362) Br J Cancer. 2022 Feb;126(2):247-258. (PMID: 34728791) Cell Rep. 2019 May 28;27(9):2649-2664.e5. (PMID: 31141689) Nature. 2013 Jun 20;498(7454):332-7. (PMID: 23722159) Cancer Res. 2016 Apr 15;76(8):2076-81. (PMID: 26964621) Nat Cancer. 2021 Dec;2(12):1338-1356. (PMID: 35121902) Oncogene. 2014 Feb 6;33(6):713-723. (PMID: 23435429) Cell. 2013 Jul 3;154(1):47-60. (PMID: 23827674) Cancer Cell. 2018 Apr 9;33(4):676-689.e3. (PMID: 29622463) Oncotarget. 2016 Nov 22;7(47):77205-77224. (PMID: 27791205) Oncotarget. 2016 Sep 27;7(39):63913-63923. (PMID: 27590505) Nat Rev Immunol. 2021 Sep;21(9):548-569. (PMID: 33833439) J Virol. 2014 May;88(10):5328-41. (PMID: 24600004) Oncoimmunology. 2019 Sep 6;8(11):1657374. (PMID: 31646083) Exp Mol Med. 2020 Apr;52(4):643-657. (PMID: 32284536) Cells. 2019 Oct 10;8(10):. (PMID: 31658669) J Immunother Cancer. 2020 Dec;8(2):. (PMID: 33268351) Genes Dev. 2007 Jul 1;21(13):1621-35. (PMID: 17606641) Nat Cancer. 2020 Feb;1(2):184-196. (PMID: 33768207) Proc Natl Acad Sci U S A. 2020 Jul 7;117(27):15923-15934. (PMID: 32571920) Int J Radiat Oncol Biol Phys. 2022 Apr 1;112(5):1243-1255. (PMID: 34986380) Proc Natl Acad Sci U S A. 2008 Nov 25;105(47):18490-5. (PMID: 19001271) J Exp Med. 2018 May 7;215(5):1287-1299. (PMID: 29622565) Nucleic Acids Res. 2022 Jun 24;50(11):6251-6263. (PMID: 35689636) Cell. 2018 Sep 6;174(6):1347-1360. (PMID: 30193109) EMBO J. 2019 Oct 4;38(21):e102718. (PMID: 31544964) Proc Natl Acad Sci U S A. 2020 May 26;117(21):11667-11673. (PMID: 32393626) Nature. 2021 Feb;590(7846):492-497. (PMID: 33505027) Genes Dev. 2007 Jun 1;21(11):1367-81. (PMID: 17510285) Trends Cancer. 2023 Jan;9(1):83-92. (PMID: 36216730) Oncogene. 2018 Apr;37(15):2037-2051. (PMID: 29367762) Dev Cell. 2020 Feb 24;52(4):413-428.e6. (PMID: 32097652) Oncotarget. 2019 Jun 25;10(41):4249-4251. (PMID: 31289622) Nature. 2013 Jun 20;498(7454):380-4. (PMID: 23722158) Mol Biol Cell. 2016 Jul 1;27(13):1981-9. (PMID: 27146113) Proc Natl Acad Sci U S A. 2009 Dec 8;106(49):20842-6. (PMID: 19926846) J Exp Med. 2019 Apr 1;216(4):867-883. (PMID: 30886058) Cancer Cell. 2022 May 9;40(5):439-440. (PMID: 35487217) Nat Immunol. 2022 Feb;23(2):287-302. (PMID: 35105987) Mol Cell. 2020 Nov 19;80(4):578-591.e5. (PMID: 33171122) Genes Dev. 2017 Feb 15;31(4):353-369. (PMID: 28279982) Nat Commun. 2014 Oct 10;5:5166. (PMID: 25300616) Science. 2017 Jan 20;355(6322):. (PMID: 28104840) Mol Cell. 2016 Oct 6;64(1):105-119. (PMID: 27666593) Nat Rev Cancer. 2009 Nov;9(11):798-809. (PMID: 19851315) Nat Commun. 2021 Sep 13;12(1):5402. (PMID: 34518527) J Natl Cancer Inst. 2016 Oct 5;109(1):. (PMID: 27707838) Sci Rep. 2022 Oct 24;12(1):17827. (PMID: 36280676) Cell Rep. 2014 Oct 9;9(1):180-192. (PMID: 25284779) Nature. 2022 Jul;607(7918):366-373. (PMID: 35705809) Nat Med. 2016 Jan;22(1):105-13. (PMID: 26618723) Nature. 2018 Jan 25;553(7689):467-472. (PMID: 29342134) Proc Natl Acad Sci U S A. 2009 May 26;106(21):8671-6. (PMID: 19458043) Proc Natl Acad Sci U S A. 2021 Jun 8;118(23):. (PMID: 34074794) Nature. 2017 Aug 24;548(7668):461-465. (PMID: 28738408) Proc Natl Acad Sci U S A. 2021 Nov 30;118(48):. (PMID: 34819364) Proc Natl Acad Sci U S A. 2004 Feb 10;101(6):1714-9. (PMID: 14755057) Nature. 2017 Aug 24;548(7668):466-470. (PMID: 28759889) Int J Oncol. 2016 Jul;49(1):381-92. (PMID: 27121503) Oncogene. 2021 Dec;40(49):6627-6640. (PMID: 34625708) Nature. 2021 Feb;590(7846):486-491. (PMID: 33505028) Immunity. 2020 Feb 18;52(2):357-373.e9. (PMID: 32049051) Radiother Oncol. 2022 Sep;174:158-167. (PMID: 35870728) Cell Rep. 2015 Aug 4;12(5):809-20. (PMID: 26212324) Immunity. 2020 May 19;52(5):767-781.e6. (PMID: 32277911) Cell Rep. 2019 Oct 29;29(5):1236-1248.e7. (PMID: 31665636) Mol Syst Biol. 2012;8:608. (PMID: 22968442) Cell Cycle. 2012 Jan 1;11(1):170-6. (PMID: 22185757) Cell Immunol. 2021 Apr;362:104298. (PMID: 33592541) Front Oncol. 2021 May 26;11:667920. (PMID: 34123836) Nat Rev Clin Oncol. 2018 Apr;15(4):234-248. (PMID: 29405201) NPJ Breast Cancer. 2021 Jun 25;7(1):81. (PMID: 34172750) Nature. 2019 Mar;567(7747):262-266. (PMID: 30842662) Biochim Biophys Acta. 2015 Nov;1852(11):2494-503. (PMID: 26303640) Nucleic Acids Res. 2012 Jan;40(1):181-95. (PMID: 21908405) Nat Rev Microbiol. 2018 Jul;16(7):423-439. (PMID: 29769653) PLoS One. 2013 Sep 05;8(9):e73710. (PMID: 24040035) Cell Rep. 2017 Dec 12;21(11):3234-3242. (PMID: 29241549) Cell. 2008 Jun 13;133(6):1019-31. (PMID: 18555778) Oncogene. 2015 Oct 8;34(41):5302-8. (PMID: 25639870) Autophagy. 2021 Dec;17(12):3976-3991. (PMID: 33752561) Immunity. 2020 Jul 14;53(1):115-126.e5. (PMID: 32640258) Sci Rep. 2022 Jun 30;12(1):10466. (PMID: 35773436) Nat Rev Cancer. 2017 Dec;17(12):709-724. (PMID: 29059149) Front Immunol. 2020 Sep 04;11:2090. (PMID: 33013881) Cancer Discov. 2013 Feb;3(2):212-23. (PMID: 23269702) Mol Cell. 2019 Jul 25;75(2):372-381.e5. (PMID: 31126740) Front Cell Dev Biol. 2021 Nov 29;9:748485. (PMID: 34926445) Immunity. 2014 Nov 20;41(5):830-42. (PMID: 25517615) J Clin Invest. 2012 Jul;122(7):2622-36. (PMID: 22706304) Cell. 2008 Jun 13;133(6):1006-18. (PMID: 18555777) Cancer Res. 2016 Nov 15;76(22):6747-6759. (PMID: 27680683) Mol Cell. 2014 May 22;54(4):626-38. (PMID: 24768535) Mol Cancer. 2019 Nov 4;18(1):152. (PMID: 31679519) Commun Biol. 2021 Jul 2;4(1):831. (PMID: 34215848) Nat Rev Immunol. 2016 Nov;16(11):661-675. (PMID: 27694913) Nat Cell Biol. 2017 Sep;19(9):1061-1070. (PMID: 28759028) Sci Rep. 2017 Feb 08;7:39858. (PMID: 28176788) Cell Death Dis. 2020 May 7;11(5):326. (PMID: 32382015) Cell. 2013 Oct 24;155(3):688-98. (PMID: 24119841) Dev Cell. 2017 Jun 19;41(6):638-651.e5. (PMID: 28633018) Life Sci Alliance. 2019 Jan 25;2(1):. (PMID: 30683688) Cell Host Microbe. 2014 Feb 12;15(2):228-38. (PMID: 24528868) Science. 2013 Feb 15;339(6121):786-91. (PMID: 23258413) EMBO J. 2021 Oct 1;40(19):e108863. (PMID: 34459017) Protein Cell. 2022 Jan;13(1):47-64. (PMID: 34676498) Nat Commun. 2017 Sep 5;8(1):427. (PMID: 28874664) Nature. 2002 Dec 19-26;420(6917):860-7. (PMID: 12490959) Cell. 2019 Jul 11;178(2):302-315.e23. (PMID: 31299200) Nat Commun. 2017 Nov 23;8(1):1736. (PMID: 29170400) Nat Chem Biol. 2014 Dec;10(12):1043-8. (PMID: 25344812) Nature. 2013 Nov 28;503(7477):530-4. (PMID: 24077100) Cell Death Differ. 2019 Mar;26(4):605-616. (PMID: 30568239) Nat Nanotechnol. 2019 Mar;14(3):269-278. (PMID: 30664751) Nat Commun. 2018 Dec 6;9(1):5226. (PMID: 30523277) Science. 2013 Feb 15;339(6121):826-30. (PMID: 23258412) Nature. 2019 Sep;573(7774):434-438. (PMID: 31511694) Hepatology. 2023 Jan 1;77(1):33-47. (PMID: 35006619) Nat Rev Immunol. 2018 May;18(5):309-324. (PMID: 29379212) Nature. 2018 Nov;563(7729):131-136. (PMID: 30356214) Proc Natl Acad Sci U S A. 2015 Dec 15;112(50):15408-13. (PMID: 26607445) Nat Commun. 2016 Aug 22;7:12513. (PMID: 27545325) Genes Dev. 2015 Oct 1;29(19):2010-21. (PMID: 26404941) Immunity. 2017 Aug 15;47(2):363-373.e5. (PMID: 28801234) Nature. 2016 May 18;533(7604):493-498. (PMID: 27225120) Cell. 2008 Feb 8;132(3):363-74. (PMID: 18267069) Sci Adv. 2021 Sep 17;7(38):eabg6908. (PMID: 34524844) Nat Cell Biol. 2020 Jul;22(7):758-766. (PMID: 32483388) Trends Cancer. 2022 Mar;8(3):174-189. (PMID: 35000881) Cancer Cell. 2018 May 14;33(5):862-873.e5. (PMID: 29706455) J Immunol. 2017 Jul 15;199(2):397-402. (PMID: 28615418) Cell Rep. 2017 May 9;19(6):1189-1201. (PMID: 28494868) J Cell Biol. 2020 Aug 3;219(8):. (PMID: 32597933) Cell. 2016 Jun 30;166(1):88-101. (PMID: 27293190) Immunity. 2022 Oct 11;55(10):1799-1812.e4. (PMID: 36070769) Nature. 2012 Jan 18;482(7383):53-8. (PMID: 22258507) J Clin Invest. 2019 Jul 25;129(10):4350-4364. (PMID: 31343989) Ann Oncol. 2015 Jul;26(7):1340-6. (PMID: 26003169) Cancer Res. 2019 Apr 1;79(7):1465-1479. (PMID: 30482772) J Cell Biol. 2013 Jul 8;202(1):129-43. (PMID: 23816621) Immunity. 2018 Sep 18;49(3):490-503.e4. (PMID: 30170810) EMBO J. 2018 Apr 13;37(8):. (PMID: 29496741) Cell Rep. 2016 Jan 12;14(2):282-97. (PMID: 26748708) Nature. 2008 Oct 2;455(7213):674-8. (PMID: 18724357) Nat Commun. 2014 Nov 04;5:5276. (PMID: 25366815) Hum Mol Genet. 2017 Oct 15;26(20):3960-3972. (PMID: 29016854) Sci Adv. 2020 Oct 14;6(42):. (PMID: 33055160) Nat Protoc. 2007;2(5):1084-104. (PMID: 17546000) Nat Commun. 2015 Jan 21;6:5990. (PMID: 25606712) mBio. 2020 Jan 28;11(1):. (PMID: 31992625) J Immunother Cancer. 2022 Sep;10(9):. (PMID: 36126994) Trends Cancer. 2016 Oct;2(10):561-571. (PMID: 28741487) Immunity. 2021 Jun 8;54(6):1154-1167.e7. (PMID: 33979578) Nature. 2015 Jun 11;522(7555):179-84. (PMID: 26017310) Cancer Discov. 2019 Jan;9(1):34-45. (PMID: 30297358) J Immunol. 2014 Nov 15;193(10):4779-82. (PMID: 25320273) Mol Ther Nucleic Acids. 2019 Mar 1;14:80-89. (PMID: 30583098) Nat Commun. 2022 Oct 10;13(1):5971. (PMID: 36216822) Nat Rev Cancer. 2021 Feb;21(2):89-103. (PMID: 33432169) EMBO J. 2021 Aug 16;40(16):e108293. (PMID: 34250619) Nat Metab. 2019 Dec;1(12):1209-1218. (PMID: 32395698) J Exp Med. 2017 Jun 5;214(6):1769-1785. (PMID: 28484079) Oncoimmunology. 2016 Feb 18;5(4):e1118599. (PMID: 27141404) Mol Cytogenet. 2019 May 14;12:17. (PMID: 31114634) Genome Res. 2017 Apr;27(4):501-511. (PMID: 28320919) Cell Host Microbe. 2015 Jun 10;17(6):811-819. (PMID: 26048136) Cancer Lett. 2019 May 28;450:110-122. (PMID: 30790684) Nature. 2017 Oct 19;550(7676):402-406. (PMID: 28976970) Nature. 2019 Jan;565(7741):659-663. (PMID: 30675059) Nat Cell Biol. 2013 Aug;15(8):978-90. (PMID: 23770676) Nat Commun. 2021 Oct 27;12(1):6207. (PMID: 34707113) Proc Natl Acad Sci U S A. 2013 Oct 29;110(44):E4134-41. (PMID: 24133140) Cell Death Differ. 2019 Sep;26(9):1735-1749. (PMID: 30568238) Cell Death Differ. 2013 Nov;20(11):1444-54. (PMID: 23933813) |
| معلومات مُعتمدة: | 224623/Z/21/Z United Kingdom WT_ Wellcome Trust; C2195/A31281 United Kingdom CRUK_ Cancer Research UK |
| فهرسة مساهمة: | Keywords: DNA synthesis and repair; cGAS-STING; chromosomal instability; immunosurveillance; innate immunity |
| المشرفين على المادة: | EC 2.7.7.- (Nucleotidyltransferases) EC 2.7.7.- (cGAS protein, human) 0 (STING1 protein, human) |
| تواريخ الأحداث: | Date Created: 20230306 Date Completed: 20230515 Latest Revision: 20230527 |
| رمز التحديث: | 20240628 |
| مُعرف محوري في PubMed: | PMC10212549 |
| DOI: | 10.1042/BST20220838 |
| PMID: | 36876871 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!